{
    "2021-12-08": [
        [
            {
                "time": "",
                "original_text": "每日一图：中国贝伐珠单抗市场方兴未艾",
                "features": {
                    "keywords": [
                        "贝伐珠单抗",
                        "中国市场",
                        "方兴未艾"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业简评报告：2021版医保目录发布 看好创新药产业链",
                "features": {
                    "keywords": [
                        "医药生物",
                        "医保目录",
                        "创新药",
                        "产业链"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2022年度策略行业策略：核心五问揆情度理 先进制造+创新升级大处落墨",
                "features": {
                    "keywords": [
                        "医药生物",
                        "年度策略",
                        "先进制造",
                        "创新升级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业海外子公司Xcovery 宣布控股Meryx公司",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "海外子公司",
                        "Xcovery",
                        "Meryx",
                        "控股"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}